US stock · Healthcare sector · Medical Devices
Company Logo

Bio-Rad Laboratories, Inc.

BIONYSE

417.14

USD
-1.10
(-0.26%)
Market Closed
-6.44P/E
27Forward P/E
-0.32P/E to S&P500
12.372BMarket CAP
- -Div Yield
Upcoming Earnings
26 Oct-31 Oct
Shares Short
Short % of Float
- -
Short % of Shares Outs.
- -
% Held by Insiders
- -
% Held by Institutions
- -
Beta
0.99
PEG Ratio
- -
52w. high/low
798.97/406.24
Avg. Daily Volume
0.15M
Return %
Stock
S&P 500
1 year
(44.59)
(16.20)
3 years
24.99
22.35
5 years
88.92
44.82
Scale: |
High
Low
115.23
66.80
109.50
60.51
100.99
51.33
125.01
80.00
126.98
84.02
118.00
91.52
127.17
106.10
134.13
102.71
152.38
112.51
184.89
122.03
273.87
181.87
345.15
220.05
376.43
223.89
648.39
309.38
832.70
545.00
752.17
406.24
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
48.30
54.75
65.34
65.11
69.66
73.97
73.14
74.61
75.32
69.19
70.25
72.84
76.73
77.46
85.52
98.18
96.14
Earnings per share
3.92
3.49
3.32
5.28
6.70
6.36
5.79
2.72
3.08
3.87
0.96
4.12
12.25
58.93
127.86
142.63
(64.57)
FCF per share
2.47
4.83
3.80
9.08
4.86
5.58
4.41
2.16
4.74
2.50
2.54
(0.38)
5.22
12.04
16.00
18.00
13.73
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
693.89
CAPEX per share
2.01
2.35
3.29
2.79
3.30
3.69
5.45
3.98
4.73
3.88
4.81
3.88
4.35
3.30
3.32
4.06
971.77
Book Value per sh.
31.07
36.41
38.54
45.97
55.55
62.21
71.08
76.50
75.67
85.33
87.87
98.81
134.75
192.84
331.90
459.12
402.71
Comm.Shares outs.
26
27
27
27
28
28
28
29
29
29
29
30
30
30
30
30
30
Avg. annual P/E ratio
17.5
23.7
26.2
14.8
14.2
17.0
17.8
43.6
39.1
35.2
155.0
53.3
22.7
5.3
3.7
4.8
(6.4)
P/E to S&P500
1.0
1.4
1.2
0.2
0.7
1.0
1.2
2.6
2.2
1.8
7.0
2.3
0.9
0.2
0.1
0.2
(0.3)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
118.9%
Revenue (m)
1,274
1,461
1,764
1,784
1,927
2,074
2,069
2,133
2,175
2,019
2,068
2,160
2,289
2,312
2,546
2,923
2,871
Operating margin
11.5%
9.3%
10.4%
12.9%
14.7%
14.2%
12.4%
7.9%
6.9%
8.3%
2.6%
5.4%
(4.5)%
9.9%
16.1%
16.7%
18.4%
Depreciation (m)
55
67
97
102
109
121
130
147
150
132
143
149
138
134
138
134
99
Net profit (m)
103
93
90
145
185
178
164
78
89
113
28
122
366
1,759
3,806
4,246
(1,942)
Income tax rate
27.3%
22.0%
31.2%
19.7%
15.1%
24.5%
26.5%
30.8%
32.5%
22.5%
32.3%
(25.0)%
28.7%
22.2%
22.4%
21.9%
(0.6)%
Net profit margin
8.1%
6.4%
5.1%
8.1%
9.6%
8.6%
7.9%
3.6%
4.1%
5.6%
1.4%
5.7%
16.0%
76.1%
149.5%
145.3%
(76.1)%
Working capital (m)
810
615
676
1,143
1,309
1,339
1,460
1,260
1,270
1,336
1,373
1,474
1,573
1,275
1,508
1,308
2,636
Long-term debt (m)
426
442
446
738
731
732
732
436
436
436
434
435
439
14
187
186
1,197
Equity (m)
820
972
1,041
1,260
1,537
1,744
2,011
2,187
2,185
2,491
2,587
2,930
4,020
5,755
9,880
13,667
8,923
ROIC
8.1%
6.1%
7.1%
8.7%
10.0%
8.3%
6.8%
4.1%
3.6%
4.0%
1.3%
4.0%
7.4%
25.0%
31.0%
24.8%
0.0%
Return on capital
8.9%
6.2%
8.2%
9.1%
9.2%
9.3%
8.0%
5.1%
4.6%
4.5%
1.6%
2.8%
9.6%
28.5%
38.0%
30.6%
0.0%
Return on equity
12.6%
9.6%
8.6%
11.5%
12.1%
10.2%
8.1%
3.6%
4.1%
4.5%
1.1%
4.2%
9.1%
30.6%
38.5%
31.1%
(21.8)%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
1,166.8%
Div.&Repurch./FCF
(15.2)%
(9.0)%
(12.6)%
(4.1)%
(9.5)%
(9.1)%
(8.4)%
(18.2)%
(11.0)%
(11.3)%
(15.1)%
38.9%
31.4%
7.8%
21.0%
9.3%
- -
Capital Structure
29 Jul · 2022 | Q2
All numbers in millions
Total liabilities
$ 3,760
Total assets
$ 12,682
Long-term debt
$ 1,197
Cash and equiv.
$ 597
Goodwill
$ 347
Retained earnings
$ 9,210
Common stock
30
Enterprise Value
$ 12,972
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
1,115
991
870
Receivables
393
419
424
Inventory
554
622
572
Other
119
109
(66)
Current assets
2,180
2,140
1,989
Acc. Payable
107
139
142
Debt due
462
38
37
Other
337
454
502
Current liabilities
905
632
681
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
14.81%
7.97%
4.07%
Cash flow
12.45%
(327.20)%
(155.20)%
Earnings
11.55%
177.02%
106.29%
Dividends
- -
- -
- -
Book value
38.33%
47.59%
25.57%
Insider Trading
Type
Shares
Date
Allison Schwartz
Exempt
80
09/05/22
Allison Schwartz
InKind
33
09/05/22
Allison Schwartz
Exempt
80
09/05/22
Schwartz Norman D
Exempt
2,600
09/05/22
Schwartz Norman D
InKind
1,575
09/05/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
572
537
647
790
2,546
2021
727
716
747
733
2,923
2022
700
691
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
23.04
32.47
44.17
28.19
127.86
2021
32.83
30.71
131.95
(52.86)
142.63
2022
(112.61)
(31.12)
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
691.13
1.40
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Medical Devices
CEO:
Mr. Norman Schwartz
Full-time employees:
7,900
City:
Hercules
Address:
1000 ALFRED NOBEL DR
IPO:
May 22, 1981
Website:
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.